Who are Terlipressin Injectable Product's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Samsca, Physulime, Vaprisol In 5% Dextrose In Plastic Container, tolvaptan+torasemide, Vasopressin administration, Tolvaptan Oral Tablet.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/terlipressin-injectable-product.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Terlipressin Injectable Product — Competitive Intelligence Brief

Terlipressin Injectable Product (Terlipressin Injectable Product) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vasopressin analogue. Area: Cardiovascular.

phase 3 Vasopressin analogue V2 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Terlipressin Injectable Product (Terlipressin Injectable Product) — Aga Khan University. Terlipressin is a synthetic analogue of vasopressin that acts as a potent vasoconstrictor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Terlipressin Injectable Product TARGET	Terlipressin Injectable Product	Aga Khan University	phase 3	Vasopressin analogue	V2 receptor
Samsca	TOLVAPTAN	Otsuka	marketed	Vasopressin V2 Receptor Antagonist [EPC]	Vasopressin V2 receptor	2009-01-01
Physulime	MOZAVAPTAN	Otsuka Pharmaceutical Co., Ltd.	marketed	mozavaptan	Vasopressin V2 receptor	2006-01-01
Vaprisol In 5% Dextrose In Plastic Container	CONIVAPTAN	Cumberland	marketed	Vasopressin Receptor Antagonist	Vasopressin V2 receptor	2005-01-01
tolvaptan+torasemide	tolvaptan+torasemide	Shanghai Chest Hospital	marketed	Combination diuretic (vasopressin V2 receptor antagonist + loop diuretic)	Vasopressin V2 receptor (tolvaptan); Na-K-Cl cotransporter (torasemide)
Vasopressin administration	Vasopressin administration	Assistance Publique Hopitaux De Marseille	phase 3	Vasopressin receptor agonist	V1A and V2 receptors
Tolvaptan Oral Tablet	Tolvaptan Oral Tablet	Otsuka Pharmaceutical Co., Ltd.	phase 3	Vasopressin V2-receptor antagonist (vaptans)	Vasopressin V2 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vasopressin analogue class)

Aga Khan University · 1 drug in this class
Shanghai Zhongshan Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Terlipressin Injectable Product — Competitive Intelligence Brief. https://druglandscape.com/ci/terlipressin-injectable-product. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab